Mozobil is a medicine used to mobilise blood stem cells from a patient’s bone marrow so that they can be collected and used later for transplantation in the same patient.
Mozobil is used together with the hormone granulocyte-colony stimulating factor (G-CSF) and is only for patients in whom collection of stem cells is difficult.
The patients who are given Mozobil are:
- adults with lymphoma or multiple myeloma (types of blood cancer);
- children from 1 year of age who have lymphoma or solid tumours.
Mozobil contains the active substance plerixafor.
The number of patients that need mobilisation and collection of haematopoietic stem cells for transplantation is low and Mozobil was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 20 October 2004. For further information on the orphan designation, see EU/3/04/227.
Mozobil : EPAR - Medicine overview (PDF/84.48 KB)
First published: 20/08/2009
Last updated: 02/09/2019
Mozobil : EPAR - Risk-management-plan summary (PDF/70.63 KB)
First published: 02/09/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Genzyme Europe BV
|Date of issue of marketing authorisation valid throughout the European Union||
09/10/2020 Mozobil - EMEA/H/C/001030 - N/0045
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.